摘要
作为造血干细胞(HSC)的重要来源之一,脐带血的临床应用受到CD34^(+)细胞剂量低、造血恢复缓慢和移植失败风险增加的限制。Omidubicel是利用烟酰胺(NAM)进行HSC体外扩增的脐带血细胞治疗产品,在同种异体HSC移植中比未经处理的脐带血植入速度更快,感染率更低。本文重点回顾Omidubicel在恶性血液病中的临床应用,总结该扩增策略的早期益处,但其对患者的长期影响仍需要大规模的临床研究进行观察。总而言之,Omidubicel的出现将扩增脐带血移植推向了移植治疗和再生医学的前沿。
The clinical application of umbilical cord blood as a source of hematopoietic stem cells(HSC)for transplantation is limited by the low dose of CD34^(+)cells,increased risk of graft failure and slow hematopoietic recovery.Omidubicel is a kind of Umbilical cord blood cell therapy product that expands hematopoietic stem cells in vitro by nicotinamide(NAM).Compared with unmanipulated Umbilical cord blood,it has faster implantation speed and a lower infection rate in allogeneic hematopoietic stem cell transplantation.Here,we focus on reviewing the relevant data on the clinical application of Omidubicel in malignant hematological diseases,and affirm the early benefits of this amplification strategy.However,its long-term impact on patients still requires large-scale clinical studies.The emergence of Omidubicel pushes expanded umbilical cord blood transplantation to the forefront of transplantation treatment and regenerative medicine.
作者
崔燕妮
任颜
梁凤婷
覃艳红
王宏伟
Cui Yanni;Ren Yan;Liang Fengting;Tan Yanhong;Wang Hongwei(Institute of Hematology of the Second Hospital of Shanxi Medical University,Taiyuan 030001,China;Shanxi Provincial Key Laboratory of Molecular Diagnosis and Treatment of Hematology Diseases,Taiyuan 030001,China;Joint Laboratory of Stem Cell Clinical Transformation and Research in Shanxi Province,Taiyuan 030001,China)
出处
《中华细胞与干细胞杂志（电子版）》
2023年第3期178-182,共5页
Chinese Journal of Cell and Stem Cell（Electronic Edition）
基金
山西省中央引导地方科技发展资金项目(YDZJSX2021B009)
山西省医学重点科技项目计划(2021XM07)。
